RxDoctor Payments Data

Pinal Doshi, MD

Internal Medicine · Cerritos, CANPI 1326062712

Payments from drug & device makers

$10,087in general payments, 2019–2025

Across 130 payments — averaging $77.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$7K
  • Pfizer$2K
  • Abbott$511
  • AstraZeneca$127
  • Merck$120
  • Sanofi-aventis U.S. LLC$73
  • plus $298 from 8 others

What the payments were for

  • Speaking & faculty fees$1,25040%
  • Food & beverage$1,78158%
  • Education$562%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,087 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$59,602
Medicare patients
139
Services billed
764

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin134$169,258
EliquisApixaban87$103,565
OzempicSemaglutide59$81,492
FarxigaDapagliflozin Propanediol65$77,411
SynjardyEmpagliflozin/Metformin Hcl36$45,702
XareltoRivaroxaban21$30,431
JanuviaSitagliptin Phosphate20$30,385
JanumetSitagliptin Phos/Metformin Hcl17$23,235
Breo ElliptaFluticasone/Vilanterol41$22,645
RybelsusSemaglutide11$20,447
Xigduo XrDapaglifloz Propaned/Metformin12$19,404
Tresiba Flextouch U-200Insulin Degludec13$17,686
TradjentaLinagliptin16$16,327
TrulicityDulaglutide15$16,000
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$15,801

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy, Tradjenta, Synjardy Xr$61$243,985201 claims
PfizerEliquis, Premarin$1,910$107,774100 claims
Novo NordiskOzempic, Rybelsus$55$101,93970 claims
AstraZenecaFarxiga, Symbicort$127$81,99780 claims
MerckJanuvia, Janumet, Dulera$120$63,85853 claims
GSKBreo Ellipta, Trelegy Ellipta, Shingrix$7,048$43,65785 claims
Johnson & JohnsonXarelto$30$30,43121 claims
Lilly USA, LLCTrulicity$13$16,00015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Cerritos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →